FDA
-
-
-
-
-
-
-
Arcellx presents data on anito-cel binder specificity at TANDEM meeting
-
-
-
-
-
-
-
Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights
-
-
-
-
-
-
-
Biotech outlook for 2025: Stifel
-
-
-
-
-
-
-
Kite (GILD) and Arcellx (ACLX) Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
-
-
-
-
-
-
-
Arcellx Inc. (ACLX) PT Raised to $81 at Needham
-
-
-
-
-
-
-
Kite and Arcellx Announce Expansion in Strategic Partnership
-
-
-
-
-
-
-
Arcellx (ACLX) Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program
-
322,240 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

